Side-by-side · Research reference
EpitalonvsRetatrutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticAUTO-DRAFTED3/37 cited
BPhase 2HUMAN-REVIEWED1/41 cited
Epitalon
Pineal bioregulator · Telomerase activator
SQ or IM · Abdomen · Daily for 10–20 days
Retatrutide
Triple-receptor agonist · Phase 3
1–12 mgWeekly dose
24.2%Body-weight ↓
~6 daysHalf-life (est)
SQ · Abdomen · Once weekly
01Mechanism of Action
Parameter
Epitalon
Retatrutide
Primary target
Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003
GLP-1R + GIPR + Glucagon receptor (triple agonism)Jastreboff 2023
Pathway
Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatonin
Triple-receptor activation → ↑insulin (GLP-1+GIP), ↓gastric emptying, ↑lipid handling, ↑energy expenditure (glucagon component)
Downstream effect
Telomere elongation, improved sleep architecture, reported lifespan extension in aged mice
Maximal weight loss across class. Glucagon component drives lipolysis and energy expenditure beyond GLP-1+GIP alone
Feedback intact?
—
—
Origin
Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)
Synthetic peptide engineered for balanced affinity at three incretin / glucagon receptors
Antibody development
—
—
02Dosage Protocols
Parameter
Epitalon
Retatrutide
Standard dose
5–10 mg / day for 10–20 days, 1–2× per year
Anecdotal community protocol. Russian clinical literature uses similar cycling.
12 mg / week (max efficacy)
Phase 2 trial dose. Phase 3 dosing TBD.
Frequency
Once daily during a cycle
Once weekly
Lower / starter dose
2.5 mg / day
—
Evidence basis
In-vitro telomerase + Russian clinical trialsKhavinson 2003
Phase 2 trial; Phase 3 ongoing
Duration
10–20 day cycles, 1–2× per year
Indefinite for chronic indication (presumed)
Reconstitution
Bacteriostatic water
Investigational; not commercially available
Timing
Pre-sleep preferred (pineal alignment)
Any time of day
Half-life
Hours (estimated)
~6 days (estimated from class)
Titration schedule
—
2 mg → 4 mg → 8 mg → 12 mg over 16 weeks
04Side Effects & Safety
Parameter
Epitalon
Retatrutide
Injection site reaction
Mild irritation
—
Sleep architecture
Improved subjective sleep quality (anecdotal)
—
Cancer risk
Theoretical via telomerase activation in pre-malignant cells
—
Long-term safety
Limited Western RCT data
—
Pregnancy / OB
Avoid
Avoid (insufficient data)
Antibody formation
Not reported
—
GI symptoms
—
Nausea, vomiting, diarrhea (very common, dose-dependent)
Heart rate
—
↑ resting HR (3–7 bpm at 12 mg)
Glucose handling
—
Glycemic improvement; rare hyperglycemia from glucagon component
Pancreatitis risk
—
Class warning
Thyroid C-cell tumours
—
Class warning (presumed)
Absolute Contraindications
Epitalon
- ·Pregnancy / breastfeeding
- ·Active malignancy or pre-malignant state
Retatrutide
- ·MTC personal or family history (presumed class effect)
- ·Pregnancy / breastfeeding
Relative Contraindications
Epitalon
- ·Family history of cancer
Retatrutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Severe cardiovascular disease (HR signal)
05Administration Protocol
Parameter
Epitalon
Retatrutide
1. Reconstitution
Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.
Investigational peptide. Research vials reconstituted with bacteriostatic water per label.
2. Injection site
SQ — abdomen preferred. Rotate sites.
SQ — abdomen, thigh, or upper arm. Rotate weekly.
3. Timing
Pre-sleep preferred to align with pineal axis.
Once weekly, same day.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
Refrigerate 2–8 °C. Light-protected.
5. Needle
29–31G, 4–8 mm insulin syringe.
27–31G, 4–8 mm insulin syringe.